Abstract: The invention relates to methods of treating cancer using novel heterocyclic glutaminase inhibitor compounds conjointly with a PD1 or PD-L1 inhibitor.

Abstract: The invention relates to methods of treating cancer or myeloproliferative diseases with a combination of a glutaminase inhibitor and a second anticancer agent such as osimertinib, pazopanib, navitoclax, palbociclib, or olaparib. The invention further relates to methods of treating cancer or myeloproliferative diseases with a combination of a glutaminase inhibitor and conventional radiotherapy or stereotactic body radiotherapy.

Abstract: The invention relates to methods of treating cancer or myeloproliferative diseaseswith a combination of a glutaminase inhibitor and an anticancer agent selected from cabozantinib, crizotinib, and axitinib. The invention further relates to methods of treating cancer or myeloproliferative diseases that are resistant to one or more anticancer agents.

Abstract: The invention relates to methods of treating cancer or myeloproliferative diseases with a combination of a glutaminase inhibitor and an anticancer agent selected from cabozantinib, crizotinib, and axitinib. The invention further relates to methods of treating cancer or myeloproliferative diseases that are resistant to one or more anticancer agents.

Abstract: The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.

Abstract: The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.

Abstract: The invention relates to method of treating a disease or disorder (e.g., such as cancer) in a subject, comprising administering to the subject heterocyclic compounds and pharmaceutical preparations described herein, if the subject is determined to possess at least one G allele at single nucleotide polymorphism (SNP) rs6983267.

Abstract: The invention relates to methods of treating cancer or myeloproliferative diseases with a combination of a glutaminase inhibitor and an anticancer agent selected from cabozantinib, crizotinib, and axitinib. The invention further relates to methods of treating cancer or myeloproliferative diseases that are resistant to one or more anticancer agents.

Abstract: Curved surfaces particularly reflectors such as concave mirror elements for use in astronomical telescopes, solar energy concentrators etc., and methods of forming such surfaces. A rigid body with a curved surface is formed by providing a mould (20) having a curved surface with a curvature opposite to that of the required curved surface, applying a vacuum to the curved surface of the mould to deform a flexible, generally planar member (14) to match the curved surface of the mould and bonding a front surface of a structurally rigid base member (12) to the opposite surface of the planar flexible member while the vacuum is applied. Peripheral casing members (16, 18) may he bonded to the base member. The base member is formed from a rigid, low-density material such as an aluminium or aluminium alloy honeycomb material. The flexible (reflective) member may comprise a thin metallic sheet such as an anodised aluminium alloy sheet, and any casing members may also be of aluminium or aluminium alloy.